Bicycle Therapeutics Signs 15-Year Contract with UK NDA for 400 Tonnes of Reprocessed Uranium
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 16 2025
0mins
Source: Newsfilter
- Long-Term Partnership: Bicycle Therapeutics has signed a 15-year contract with the UK Nuclear Decommissioning Authority, securing access to up to 400 tonnes of reprocessed uranium, which will provide a sustainable raw material supply for its potential lifesaving therapies, significantly enhancing the company's R&D capabilities.
- Radioisotope Development: Through collaboration with the UK National Nuclear Laboratory, Bicycle plans to extract 228Th from the reprocessed uranium, further processing it into a 212Pb generator, with the potential to deliver tens of thousands of doses of 212Pb annually, advancing targeted cancer therapies.
- Customized Generator: Bicycle has partnered with SpectronRx to develop a bespoke 212Pb generator, with initial quantities of 212Pb successfully produced, which will provide strong support for the company's competitive position in the radiopharmaceutical market.
- Strategic Investment Outlook: The CEO of Bicycle stated that these collaborations demonstrate the company's potential in radiopharmaceutical R&D, with expectations to advance its BRC product line and present initial human imaging data in the first half of 2026, further solidifying its market position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BCYC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BCYC
Wall Street analysts forecast BCYC stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 4.380
Low
24.00
Averages
24.00
High
24.00
Current: 4.380
Low
24.00
Averages
24.00
High
24.00
About BCYC
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tarsus Pharmaceuticals Shares Surge 7.5% on Strong Sales Growth
- Stock Surge: Tarsus Pharmaceuticals (TARS) shares rose 7.5% to $65.44 in the last trading session, with significantly higher trading volume indicating increased investor confidence in the company's prospects.
- Strong Product Sales: Xdemvy (lotilaner ophthalmic solution) achieved net sales of $145.4 million in Q1 2026, reflecting over 85% year-over-year growth, driven by broader screening and prescribing by eye care professionals across a wider patient base.
- Global Expansion Plans: Tarsus received regulatory approval for Xdemvy in China, triggering a $15 million milestone payment, while ongoing regulatory progress in Europe and Japan supports the product's long-term commercial opportunities, highlighting its potential for global market expansion.
- Pipeline Development: The company is evaluating TP-04 and TP-05 in mid-stage studies for treating ocular rosacea and Lyme disease, with topline data expected in the first half of 2027, further enhancing investor confidence in its future growth trajectory.
See More
Kymera Therapeutics Appoints New Chairman of the Board
- Board Leadership Change: Kymera Therapeutics announced the appointment of Felix J. Baker as the new Chairman of the Board, succeeding Bruce Booth, who has held the position since 2016 and will remain on the Board as an Independent Director, ensuring continuity and stability in corporate governance.
- Management Background: Baker has served as the company's Lead Independent Director since 2024 and is a Managing Member of Baker Brothers Investment, co-founded in 2000, which brings extensive experience in biopharmaceutical investments, likely providing stronger strategic guidance for Kymera.
- Stock Performance: Kymera's stock has traded between $36.65 and $105 over the past year, closing at $99.87, up 1.65% from the previous day, indicating market confidence in the company's future prospects.
- After-Hours Trading Dynamics: In after-hours trading, Kymera's shares rose 0.33% to $100.20, reflecting investor optimism regarding the new Chairman's appointment, which may further drive stable growth in the company's stock price.
See More
Bicycle Therapeutics Reports Q1 Earnings Miss
- Earnings Report Disappointment: Bicycle Therapeutics reported a Q1 GAAP EPS of -$0.87, missing estimates by $0.20, indicating ongoing challenges in profitability that could undermine investor confidence.
- Significant Revenue Decline: The company generated $0.89M in revenue for Q1, a staggering 91.1% year-over-year drop, falling short of expectations by $6.61M, which highlights severe deficiencies in market demand and product sales that may lead to liquidity issues in the future.
- Cash Reserves Status: As of March 31, 2026, Bicycle Therapeutics held $559.5M in cash and cash equivalents, with an expected runway into 2030, providing a buffer for operations despite current financial strains.
- Strategic Shift and Layoffs: The company announced a shift in priorities and layoffs, indicating proactive measures to address its financial challenges, aiming to enhance operational efficiency through optimized resource allocation.
See More
Bicycle Therapeutics Presents Five Abstracts at AACR Annual Meeting 2026
- Presentation Schedule: Bicycle Therapeutics will showcase five studies at the AACR Annual Meeting 2026 from April 17-22, highlighting its latest advancements in cancer therapeutics, which is expected to attract industry attention and enhance the company's visibility.
- Key Research Findings: One oral presentation will focus on the anti-tumor activity of BT5528 in head and neck squamous cell carcinoma models, demonstrating its potential in preclinical studies and possibly laying the groundwork for subsequent clinical trials.
- Diverse Research Topics: Other poster presentations will include preliminary results of BT5528 in combination with nivolumab and studies on EphA2 expression in muscle-invasive bladder cancer, showcasing the company's broad application potential across various cancer types.
- Technological Innovation Context: Bicycle Therapeutics is dedicated to developing Bicycle® molecules, leveraging its unique bicyclic peptide technology to target traditionally undruggable targets like EphA2, demonstrating its innovative capabilities and competitive edge in the oncology market.
See More
Bicycle Therapeutics Restructures and Lays Off 30% of Workforce
- Strategic Restructuring: Bicycle Therapeutics announced a reprioritization of certain programs and a layoff of approximately 30% of its workforce to focus on its most promising candidates, resulting in an expected 50% reduction in annual operating expenses.
- Pipeline Focus: The company will concentrate its research efforts on BT5528 (also known as nuzefatide pevedotin), a potentially first-in-class EphA2-targeting drug conjugate currently in phase I/II clinical trials, aimed at treating metastatic pancreatic ductal adenocarcinoma, indicating strong market potential.
- Clinical Trial Progress: BT5528 is being tested as a monotherapy and in combination with an immune checkpoint inhibitor in phase I/II trials, while also undergoing a phase II trial as a monotherapy for metastatic pancreatic ductal adenocarcinoma, showcasing its potential in cancer treatment.
- Asset De-prioritization: Bicycle Therapeutics will deprioritize its most advanced drug conjugate, zelenectide pevedotin, which targets Nectin-4 expressing tumors and was previously in a phase II trial for metastatic urothelial cancer, reflecting the company's strategic resource allocation adjustments.
See More
Bicycle Therapeutics Q4 Earnings Exceed Expectations
- Strong Earnings Report: Bicycle Therapeutics reported a Q4 GAAP EPS of -$0.29, beating expectations by $0.66, indicating a significant improvement in financial performance and reflecting the potential value of its business model.
- Revenue Surge: The company achieved Q4 revenue of $47.96 million, a staggering 1192.7% year-over-year increase, surpassing market expectations by $40.88 million, demonstrating robust demand and rapid growth for its products or services.
- Healthy Cash Position: As of December 31, 2025, Bicycle Therapeutics holds $628 million in cash and cash equivalents, with an expected cash runway extending into 2030, enhancing the company's flexibility for future investments and operations.
- Strategic Restructuring Plan: The company plans to reduce its workforce by approximately 30% to optimize resource allocation and improve operational efficiency, a move that not only helps lower costs but may also enhance the company's long-term sustainability in the competitive biopharmaceutical industry.
See More
Tarsus Pharmaceuticals Shares Surge 7.5% on Strong Sales Growth
- Stock Surge: Tarsus Pharmaceuticals (TARS) shares rose 7.5% to $65.44 in the last trading session, with significantly higher trading volume indicating increased investor confidence in the company's prospects.
- Strong Product Sales: Xdemvy (lotilaner ophthalmic solution) achieved net sales of $145.4 million in Q1 2026, reflecting over 85% year-over-year growth, driven by broader screening and prescribing by eye care professionals across a wider patient base.
- Global Expansion Plans: Tarsus received regulatory approval for Xdemvy in China, triggering a $15 million milestone payment, while ongoing regulatory progress in Europe and Japan supports the product's long-term commercial opportunities, highlighting its potential for global market expansion.
- Pipeline Development: The company is evaluating TP-04 and TP-05 in mid-stage studies for treating ocular rosacea and Lyme disease, with topline data expected in the first half of 2027, further enhancing investor confidence in its future growth trajectory.
See More
Kymera Therapeutics Appoints New Chairman of the Board
- Board Leadership Change: Kymera Therapeutics announced the appointment of Felix J. Baker as the new Chairman of the Board, succeeding Bruce Booth, who has held the position since 2016 and will remain on the Board as an Independent Director, ensuring continuity and stability in corporate governance.
- Management Background: Baker has served as the company's Lead Independent Director since 2024 and is a Managing Member of Baker Brothers Investment, co-founded in 2000, which brings extensive experience in biopharmaceutical investments, likely providing stronger strategic guidance for Kymera.
- Stock Performance: Kymera's stock has traded between $36.65 and $105 over the past year, closing at $99.87, up 1.65% from the previous day, indicating market confidence in the company's future prospects.
- After-Hours Trading Dynamics: In after-hours trading, Kymera's shares rose 0.33% to $100.20, reflecting investor optimism regarding the new Chairman's appointment, which may further drive stable growth in the company's stock price.
See More
Bicycle Therapeutics Reports Q1 Earnings Miss
- Earnings Report Disappointment: Bicycle Therapeutics reported a Q1 GAAP EPS of -$0.87, missing estimates by $0.20, indicating ongoing challenges in profitability that could undermine investor confidence.
- Significant Revenue Decline: The company generated $0.89M in revenue for Q1, a staggering 91.1% year-over-year drop, falling short of expectations by $6.61M, which highlights severe deficiencies in market demand and product sales that may lead to liquidity issues in the future.
- Cash Reserves Status: As of March 31, 2026, Bicycle Therapeutics held $559.5M in cash and cash equivalents, with an expected runway into 2030, providing a buffer for operations despite current financial strains.
- Strategic Shift and Layoffs: The company announced a shift in priorities and layoffs, indicating proactive measures to address its financial challenges, aiming to enhance operational efficiency through optimized resource allocation.
See More
Bicycle Therapeutics Presents Five Abstracts at AACR Annual Meeting 2026
- Presentation Schedule: Bicycle Therapeutics will showcase five studies at the AACR Annual Meeting 2026 from April 17-22, highlighting its latest advancements in cancer therapeutics, which is expected to attract industry attention and enhance the company's visibility.
- Key Research Findings: One oral presentation will focus on the anti-tumor activity of BT5528 in head and neck squamous cell carcinoma models, demonstrating its potential in preclinical studies and possibly laying the groundwork for subsequent clinical trials.
- Diverse Research Topics: Other poster presentations will include preliminary results of BT5528 in combination with nivolumab and studies on EphA2 expression in muscle-invasive bladder cancer, showcasing the company's broad application potential across various cancer types.
- Technological Innovation Context: Bicycle Therapeutics is dedicated to developing Bicycle® molecules, leveraging its unique bicyclic peptide technology to target traditionally undruggable targets like EphA2, demonstrating its innovative capabilities and competitive edge in the oncology market.
See More
Bicycle Therapeutics Restructures and Lays Off 30% of Workforce
- Strategic Restructuring: Bicycle Therapeutics announced a reprioritization of certain programs and a layoff of approximately 30% of its workforce to focus on its most promising candidates, resulting in an expected 50% reduction in annual operating expenses.
- Pipeline Focus: The company will concentrate its research efforts on BT5528 (also known as nuzefatide pevedotin), a potentially first-in-class EphA2-targeting drug conjugate currently in phase I/II clinical trials, aimed at treating metastatic pancreatic ductal adenocarcinoma, indicating strong market potential.
- Clinical Trial Progress: BT5528 is being tested as a monotherapy and in combination with an immune checkpoint inhibitor in phase I/II trials, while also undergoing a phase II trial as a monotherapy for metastatic pancreatic ductal adenocarcinoma, showcasing its potential in cancer treatment.
- Asset De-prioritization: Bicycle Therapeutics will deprioritize its most advanced drug conjugate, zelenectide pevedotin, which targets Nectin-4 expressing tumors and was previously in a phase II trial for metastatic urothelial cancer, reflecting the company's strategic resource allocation adjustments.
See More
Bicycle Therapeutics Q4 Earnings Exceed Expectations
- Strong Earnings Report: Bicycle Therapeutics reported a Q4 GAAP EPS of -$0.29, beating expectations by $0.66, indicating a significant improvement in financial performance and reflecting the potential value of its business model.
- Revenue Surge: The company achieved Q4 revenue of $47.96 million, a staggering 1192.7% year-over-year increase, surpassing market expectations by $40.88 million, demonstrating robust demand and rapid growth for its products or services.
- Healthy Cash Position: As of December 31, 2025, Bicycle Therapeutics holds $628 million in cash and cash equivalents, with an expected cash runway extending into 2030, enhancing the company's flexibility for future investments and operations.
- Strategic Restructuring Plan: The company plans to reduce its workforce by approximately 30% to optimize resource allocation and improve operational efficiency, a move that not only helps lower costs but may also enhance the company's long-term sustainability in the competitive biopharmaceutical industry.
See More
